D-Gen Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

D-Gen General Information

Description

Operator of a research-based bio-medical company intended to offer neurological treatment alternatives. The company's bio-medical firm researches in prion disease and other neurodegenerative diseases including Alzheimer's disease and develops diagnostic therapeutics, enabling medical professionals to treat nervous system diseases.

Contact Information

Website
www.d-gen.co.uk
Formerly Known As
Boardpaper, Neurogene
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Box 118, Institute of Neurology
  • National Hospital for Neurology and Neurosurgery, Queen Square
  • London WC1N 3BG
  • England, United Kingdom
+44 020
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Box 118, Institute of Neurology
  • National Hospital for Neurology and Neurosurgery, Queen Square
  • London WC1N 3BG
  • England, United Kingdom
+44 020

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

D-Gen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jan-2019 Completed Out of Business
3. Later Stage VC Completed Generating Revenue
2. Later Stage VC 27-Nov-2012 $19.2K $84.4K Completed Generating Revenue
1. Angel (individual) 17-Aug-2011 $65.3K $65.3K Completed Generating Revenue
To view D-Gen’s complete valuation and funding history, request access »

D-Gen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 1
Ordinary
To view D-Gen’s complete cap table history, request access »

D-Gen Patents

  • 83

    Total Documents Applications and Grants

  • Total Patents Families

  • 25

    Granted

  • Pending

  • Expiring in next 12 mo

D-Gen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2611346-T3 Antibodies against prion protein for the treatment of alzheimer's disease Active 18-May-2011
GB-201108490-D0 Methods and uses Inactive 18-May-2011
EP-2709660-A1 Prion protein antibodies for the treatment of alzheimer's disease Active 18-May-2011
EP-2709660-B1 Prion protein antibodies for the treatment of alzheimer's disease Active 18-May-2011
US-10316099-B2 Prion protein antibodies for the treatment of alzheimer's disease Inactive 18-May-2011 C07K16/2872
To view D-Gen’s complete patent history, request access »

Ready to get started?

Request a free trial

D-Gen FAQs

  • When was D-Gen founded?

    D-Gen was founded in 2000.

  • Where is D-Gen headquartered?

    D-Gen is headquartered in London, United Kingdom.

  • What industry is D-Gen in?

    D-Gen’s primary industry is Biotechnology.

  • Is D-Gen a private or public company?

    D-Gen is a Private company.

  • What is D-Gen’s current revenue?

    The current revenue for D-Gen is .

  • How much funding has D-Gen raised over time?

    D-Gen has raised $84.4K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »